story_b1dcdd14-aa90-540c-a5a8-1c10ea987a9aLilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer
Verified signal
cand_6ce27a9f-a766-57cb-8594-b42fb1547a71: 1 verified canonical event across 1 event type, supported by 1 independent source domain.
Why it matters
Verified with 1 independent source domain, 5 evidence object(s), 2 grounded fact(s), and confidence 0.80.
Evidence graph
evt_9cc28b53-cede-535f-aa1f-ddefb0c5f78cevd_01d28f85-fc8b-5088-ab85-3954de0c7441, evd_63dece49-295e-5f83-a40e-1ffeed792bc0, evd_cc37a131-9b18-5fed-b93e-02391e833a32, evd_d3b5a55a-2ddb-5c8e-9898-215ae8f4744b, evd_d7a7689f-efab-5309-baa1-3e1d2988b78cfact_8a9b31d1-32c2-5cbd-830e-c1e75338796e, fact_98cd76a3-c930-58ca-b25e-976284d6edd6rel_081ef461-3605-5b58-9515-1f1de0f70d40, rel_1990447d-d3e8-59ff-a17d-3d5ddcae19f1